Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

ABSTRACT Proteolysis‐targeting chimera (PROTAC) have emerged as a promising class of anticancer agents. Eukaryotic elongation factor 2 kinase (eEF2K), a stress‐responsive regulator of translational elongation, has emerged as a pivotal therapeutic target in triple‐negative breast cancer (TNBC) due to...

Descripció completa

Dades bibliogràfiques

Autors principals:	Shijun Cao, Changxin Zhong, Shilong Jiang, Yungui Li, Yang Xi, Mingxuan Xiao, Ting Jiang, Xiaoya Wan, Zonglin Chen, Xiaohui Yu, Yan Cheng
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-03-01
Col·lecció:	Advanced Science
Matèries:	A6 A6@ZIF‐8 eEF2K PROTAC Triple‐negative breast cancer
Accés en línia:	https://doi.org/10.1002/advs.202520863
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!